-
1
-
-
0035812751
-
Harnessing genomics and biotechnology to improve global health equity
-
DOI 10.1126/science.1062633
-
Singer P.A., Daar A.S.: Harnessing genomics and biotechnology to improve global health equity. Science, 2001; 294: 87-89. (Pubitemid 32952953)
-
(2001)
Science
, vol.294
, Issue.5540
, pp. 87-89
-
-
Singer, P.A.1
Daar, A.S.2
-
2
-
-
2942612270
-
-
ISPOR Book of Terms, Lavrenceville, USA
-
Berger M.L., Bingefors K., Hedblom E. et al.: Health Care Cost, Quality and outcomes. ISPOR Book of Terms, Lavrenceville, USA, 2003.
-
(2003)
Health Care Cost, Quality and Outcomes
-
-
Berger, M.L.1
Bingefors, K.2
Hedblom, E.3
-
4
-
-
0242270743
-
Defining and characterizing the late-stage biopharmaceutical pipeline
-
Nagle P.C., Lugo T.F., Nicita C.A.: Defining and characterizing the late-state biopharmaceutical pipeline. Am. J. Manag. Care, 2003; 9(suppl): S124-35. (Pubitemid 37345200)
-
(2003)
American Journal of Managed Care
, vol.9
, Issue.SUPPL. 6
-
-
Nagle, P.C.1
Lugo, T.F.2
Nicita, C.A.3
-
5
-
-
25844463410
-
Adverse reactions to biologic agents: Focus on autoimmune disease therapies
-
DOI 10.1016/j.jaci.2005.03.028, PII S0091674905006056
-
Lee S.J, Kavanaugh A.: Adverse reactions to biologic agents: Focus on autoimmune disease therapies. J. Allergy Clin. Immunol., 2005;116:900-5. (Pubitemid 41400558)
-
(2005)
Journal of Allergy and Clinical Immunology
, vol.116
, Issue.4
, pp. 900-905
-
-
Lee, S.J.1
Kavanaugh, A.2
-
6
-
-
33745786806
-
Adverse side-effects to biological agents
-
Pichler W. J.: Adverse side-effects to biological agents. Allergy, 2006; 61, 8: 912-920.
-
(2006)
Allergy
, vol.61
, Issue.8
, pp. 912-920
-
-
Pichler, W.J.1
-
7
-
-
84882124318
-
Adverse Side Effects to Biological Agents
-
Pichler W.J. (ed.): Basel, Karger
-
Pichler J.W., Campi P.: Adverse Side Effects to Biological Agents. - in - Pichler W.J. (ed.): Drug Hypersensitivity. Basel, Karger, 2007, 151-165.
-
(2007)
Drug Hypersensitivity
, pp. 151-165
-
-
Pichler, J.W.1
Campi, P.2
-
9
-
-
84863742845
-
Ranibizumab (Lucentis) w leczeniu neowaskularnej (wysiekowej) postaci zwyrodnienia plamki zwia̧zanego z wiekiem (AMD): Dowody uzyskane z badań klinicznych
-
doi: 10.1136/bjo.2009.159160
-
Mitchell P., Korobelnik P., Lanzetta P. et al.: Ranibizumab (Lucentis) w leczeniu neowaskularnej (wysiekowej) postaci zwyrodnienia plamki zwia̧zanego z wiekiem (AMD): dowody uzyskane z badań klinicznych. BJO, 2009; doi: 10.1136/bjo.2009.159160.
-
(2009)
BJO
-
-
Mitchell, P.1
Korobelnik, P.2
Lanzetta, P.3
-
10
-
-
34247276688
-
Zastosowanie leków biologicznych w dermatologii
-
Pełka M., Broniarczyk-Dyła G.: Zastosowanie leków biologicznych w dermatologii. Post. Dermatol. Alergol., 2007; 24/1:35-41.
-
(2007)
Post. Dermatol. Alergol.
, vol.24
, Issue.1
, pp. 35-41
-
-
Pełka, M.1
Broniarczyk-Dyła, G.2
-
11
-
-
11944253597
-
Biological agents in rheumatoid arthritis
-
Shankar S., Handa R.: Biological agents in rheumatoid arthritis. J. Postgrad. Med., 2004; 50: 293-299. (Pubitemid 40101229)
-
(2004)
Journal of Postgraduate Medicine
, vol.50
, Issue.4
, pp. 293-299
-
-
Shankar, S.1
Handa, R.2
-
12
-
-
77956985320
-
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: A longitudinal observational study
-
Wolfe F., Michaud K.: The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthr. Res. Ther., 2010; 12: R35.
-
(2010)
Arthr. Res. Ther.
, vol.12
-
-
Wolfe, F.1
Michaud, K.2
-
13
-
-
84863767743
-
-
http://www.upmccancercenters.com/cainformation/biologictherapy.html
-
-
-
-
14
-
-
84863749285
-
-
http://www.imshealth.com
-
-
-
-
15
-
-
0034529448
-
Immunological principles of adverse drug reactions: The initiation and propagation of immune responses elicited by drug treatment
-
Naisbitt D.J., Gordon S.F., Pirmohamed M. et al.: Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf., 2000; 23: 483-507. (Pubitemid 32001512)
-
(2000)
Drug Safety
, vol.23
, Issue.6
, pp. 483-507
-
-
Naisbitt, D.J.1
Gordon, S.F.2
Pirmohamed, M.3
Park, B.K.4
-
16
-
-
34447299908
-
The spectrum and types of adverse side effects to biological immune modulators: A proposal for new classification
-
Zemkova M., Jebavy L., Kotlarova J. et al.: The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification. Folia Biologica (Praha), 2007; (53): 146-155. (Pubitemid 47054484)
-
(2007)
Folia Biologica
, vol.53
, Issue.4
, pp. 146-155
-
-
Zemkova, M.1
Jebavy, L.2
Kotlarova, J.3
Vlcek, J.4
Meyboom, R.H.B.5
-
17
-
-
77953563408
-
The complex clinical picture of side effects to biologicals
-
Hausmann O.V., Seitz M., Villiger P.M. et al.: The complex clinical picture of side effects to biologicals. Med. Clin. North Am., 2010; 94: 791-804.
-
(2010)
Med. Clin. North Am.
, vol.94
, pp. 791-804
-
-
Hausmann, O.V.1
Seitz, M.2
Villiger, P.M.3
-
18
-
-
79955573063
-
Immediate adverse reactions to biological: From pathogenic mechanisms to prophylactic management
-
Vultaggio A., Maggi E., Matucci A.: Immediate adverse reactions to biological: from pathogenic mechanisms to prophylactic management. Curr. Opin. Clin. Immunol., 2011; 11: 262-268.
-
(2011)
Curr. Opin. Clin. Immunol.
, vol.11
, pp. 262-268
-
-
Vultaggio, A.1
Maggi, E.2
Matucci, A.3
-
19
-
-
0029859871
-
Type 1, and Type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
-
Lucey D.R., Clerici M., Shearer G.M.: Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev., 1996; 9:532-562. (Pubitemid 26366537)
-
(1996)
Clinical Microbiology Reviews
, vol.9
, Issue.4
, pp. 532-562
-
-
Lucey, D.R.1
Clerici, M.2
Shearer, G.M.3
-
20
-
-
72149112759
-
Autoimmune diseases induced by biological agents. A double-edged sword?
-
Ramos-Casals M., Perez-Alvarez R., Diaz-Lagares C. et al.: Autoimmune diseases induced by biological agents. A double-edged sword? Autoimm. Rev., 2010 (9); 188-193.
-
(2010)
Autoimm. Rev.
, Issue.9
, pp. 188-193
-
-
Ramos-Casals, M.1
Perez-Alvarez, R.2
Diaz-Lagares, C.3
-
22
-
-
77956334120
-
Mapping the safety profile of biological. A disproportionality analysis using the WHO adverse drug reaction database, VigiBase
-
Giezen T.J., Mantel-Teeuwisse A.K., Meyboom R.H.B. et al.: Mapping the safety profile of biological. A disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf., 2010; 33 (10): 865-878.
-
(2010)
Drug Saf.
, vol.33
, Issue.10
, pp. 865-878
-
-
Giezen, T.J.1
Mantel-Teeuwisse, A.K.2
Meyboom, R.H.B.3
|